MedPath

Quality Control of CE-Certified Phonak Hearing Aids - 2018_07

Not Applicable
Completed
Conditions
Hearing Loss, Sensorineural
Interventions
Device: Virto B-Titanium
Device: Extension of Virto B-Titanium
Registration Number
NCT03555084
Lead Sponsor
Sonova AG
Brief Summary

Phonak Hearing Systems pass through different development and study stages. At an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner. If the benefit is proven, their performance is then investigated regarding interdependency between all available algorithms, features and functions running in parallel in a hearing aid (pivotal/pre-validation studies) and, as a result, they get optimized. Afterwards, and prior to product launch, the Phonak Hearing Systems undergo a final quality control in terms of clinical trials. This is a pre-validation study, investigating optimized algorithms, features, functions and wearing comfort. This will be a clinical evaluation which will be conducted mono centric at Sonova AG Headquarters based in Stäfa (Switzerland).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
16
Inclusion Criteria
  • Adult hearing impaired persons (minimum age: 18 years) with or without experience with hearing aids
  • Good written and spoken (Swiss) German language skills
  • Healthy outer ear
  • Ability to fill in a questionnaire (p/eCRF) conscientiously
  • willingness to wear custom made Hearing aids
  • Informed Consent as documented by signature
  • Benefit with TFG tool at least on one ear
Exclusion Criteria
  • Contraindications to the MD in this study, e.g. known hypersensitivity or allergy to the investigational product
  • Limited mobility and not in the position to attend weekly appointments in Stäfa (Switzerland)
  • Limited ability to describe listening impressions/experiences and the use of the hearing aid
  • Inability to produce a reliable hearing test result
  • Limited dexterity (not able to change a 10size Hearing aid battery)
  • no Benefit of the TFG tool on both ears
  • Known psychological problems
  • Central hearing disorders

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Device: Phonak Virto B-TitaniumVirto B-TitaniumThe Phonak Virto B-Titanium will be fitted to the participants individual Hearing loss.
Device: Extension of Phonak Virto B-TitaniumExtension of Virto B-TitaniumThe extension of Phonak Virto B-Titanium will be fitted to the participants individual Hearing loss.
Primary Outcome Measures
NameTimeMethod
Visibility and Wearing Comfort3 weeks

The primary objective of this study is to evaluate if Virto B-Titanium hearing aids measured with the Titanium FitGuide (TFG) (extension of Virto B-Titanium) are less visible (deeper) than modeling without TFG (Virto B-Titanium) while maintaining wearing comfort on adult participants (new and existing users) with mild to moderately-severe hearing loss (M and P receiver ).

Secondary Outcome Measures
NameTimeMethod
Measurement of acoustic Feedback Thresholds3 weeks

Secondary objective is to compare the acoustic feedback thresholds of the TFG- and without TFG- modeled devices in regard of an adequate sealing effect of the respective devices. Thereby, feedback thresholds, measured with the Phonak Target fitting software, must be comparable to average feedback threshold values of the respective shell forms (IIC / CIC). Acceptable feedback thresholds must guarantee an insertion gain \[in dB SPL\] of at least 20 dB in a specific frequency range.

Trial Locations

Locations (1)

Sonova AG

🇨🇭

Stäfa, Zürich, Switzerland

© Copyright 2025. All Rights Reserved by MedPath